Ethics Committee Number	IRAS Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site confirmed by Sponsor	Date Site confirmed	Date Site Ready to Start	Date of First Patient Recruited	Source of Delay	Comments
20/NS/0029	277157	Real-world evidence study of primary care referrals to NHS memory clinics and the clinical and economic case for the adoption of the Integrated Cognitive Assessment to improve the dementia diagnosis pathway (ADePT)	23/04/2021	23/04/2021	27/02/2021	08/07/2021	07/07/2021	15/07/2021	13/09/2021		
21/WA/0151	287976	A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer s type, 20-AVP-786-306	04/01/2021	24/08/2021	17/08/2021	25/08/2021	24/09/2021	23/11/2021	N/A	NHS Provider	Site confirmed on 24.09.2021 (contract signed) but the study opening was delayed until 23.11.2021 due to key contact unavailability. Study has been awaiting 56 days to recruit the first participant considering the current opening date
21/FT/0050	294543	A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer s disease (EVOKE plus)	28/05/2021	28/05/2021	20/05/2021	14/12/2021	16/12/2021	17/12/2021	N/A	Neither	Portacabin used at the research site to conduct the study was flooded and the local team was awating for the estates to solve the problem. The issue has now been resolved.
21/FT/0049	294544	A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer s disease (EVOKE)	28/04/2021	24/05/2021	20/05/2021	14/12/2021	16/12/2021	17/12/2021	N/A	Neither	Portacabin used at the research site to conduct the study was flooded and the local team was awating for the estates to solve the problem. The issue has now been resolved.
21/LO/0621	301803	A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy	26/08/2021	26/08/2021	15/11/2021	13/12/2021	06/01/2022	06/01/2022	N/A	Sponsor	Strict eligibility criteria. The current healthcare path for adolescents affected by Major Depressive Disorder includes one of the drugs indicated in the exclusion criteria for the study, so this reduces considerably the possibility of finding suitable participants. The local PI has requested a change in the eligibility criteria to the sponsor.